Answers are grounded in this paper and cite their sources.
The subject of this application is N(4)-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N(2)-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine xinafoate salt, as well as inhalant formulations of the salt and a process for the preparation of the salt. This salt is probably R-343, a Syk kinase inhibitor being developed under license by Pfizer, an inhaled formulation of which is in Phase I development for the treatment of asthma.
No takes yet. Share an insight, caveat, or question.
Peter Norman (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: